Lack Of Facts Dooms Class Cert Over Takeda Gout Drug

By Bryan Koenig (November 28, 2022, 9:16 PM EST) -- A federal judge last week rejected a bid by pharmacy chain Value Drug Co. to certify a class of roughly 50 purchasers of Takeda Pharmaceuticals' anti-gout drug Colcrys alleging that the company engaged in anticompetitive deals to stave off generic competition....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!